http://pharmexec.findpharma.com/pharmexec/News+Analysis/Article/list/43753 The latest business, scientific & regulatory news from the pharmaceutical and biotechnology industries. 2009-11-21T18:51:35Z http://pharmexec.findpharma.com/pharmexec/Marketing/A-Call-for-Social-Media-Guidelines/ArticleStandard/Article/detail/642665?contextCategoryId=43753&ref=25 Nearly 70 pharma execs, new media mavens, and even Joe Q. Public packed last week's FDA social media hearings to plead for some form of guidance on how to handle Tweets, blog comments, and off label discussions online. 2009-11-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472009/642665null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Clinical-Trials-Find-Drug-Effective-In-Increasing-/ArticleStandard/Article/detail/642664?contextCategoryId=43753&ref=25 Dubbed as the 'female Viagra,' Boehringer Ingelheim's filbanserin represents an unprecedented step forward in treating female sexual dysfunction. 2009-11-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/472009/642664null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Quick-on-the-Draw-with-RampD-Location-Plans/ArticleStandard/Article/detail/640996?contextCategoryId=43753&ref=25 Following through with its promise to waste no time in merging Wyeth and Pfizer, the pharma giant announced restructuring plans for its global research network. 2009-11-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462009/640996null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GSK-Donates-50-Million-H1N1-Doses-To-WHO/ArticleStandard/Article/detail/640997?contextCategoryId=43753&ref=25 Developing countries will receive the scarce vaccine for free, as GSK remains confident it will fulfill contractual vaccine obligations around the world. 2009-11-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/462009/640997null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/JampJ-Cuts-Staff-in-Major-Restructuring-Move/ArticleStandard/Article/detail/639344?contextCategoryId=43753&ref=25 Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce. 2009-11-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/452009/639344null HTML http://pharmexec.findpharma.com/pharmexec/Deals/Glaxo-Vies-for-a-Second-Act-in-HIV/ArticleStandard/Article/detail/639343?contextCategoryId=43753&ref=25 A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much. 2009-11-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/452009/639343null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Sanofi-Warned-for-Misleading-Tent-Card/ArticleStandard/Article/detail/637273?contextCategoryId=43753&ref=25 Sure, prescription information for Sanofi-Aventis's Uroxatral appears on the back of the tent card, but how can consumer?s see it if it's mounted to a pharmacy wall? 2009-10-28T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/442009/637273null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GAO-Accuses-FDA-of-Tardy-Trial-Data/ArticleStandard/Article/detail/637272?contextCategoryId=43753&ref=25 The US oversight arm scripted a hefty report complaining that FDA is not moving fast enough when it comes to screening clinical trials data for drugs green lit through its expedited approval program. 2009-10-28T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/442009/637272null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/CROs-United/ArticleStandard/Article/detail/636759?contextCategoryId=43753&ref=25 US-based CRO, Health Decisions, hopes to raise the efficacy standards for complex studies and help companies get products to market faster by establishing an international network of CROs. 2009-10-27T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/442009/636759null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/UKs-NICE-Rejects-GSK-Breast-Cancer-Treatment/ArticleStandard/Article/detail/635531?contextCategoryId=43753&ref=25 21 October 2009-10-21T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/432009/635531null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Jury-Sides-with-Family-in-Paxil-Birth-Defect-Case/ArticleStandard/Article/detail/634103?contextCategoryId=43753&ref=25 GSK is being ordered to pay $2.5 million in restitution to a Pennsylvania family. The firm was accused of not doing enough to warn consumers that taking the antidepressant Paxil, while pregnant, could lead to birth defects. 2009-10-14T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422009/634103null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Sandoz-and-Shire-settle-Adderall-XR-Dispute/ArticleStandard/Article/detail/634102?contextCategoryId=43753&ref=25 Sandoz Shire Pharmaceuticals announced that it would allow Sandoz to market a generic version of its blockbuster ADHD med Adderall XR if it can clear FDA. But that's a big if. 2009-10-14T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422009/634102null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Economist-Award-for-Bioscience-Announced/ArticleStandard/Article/detail/633542?contextCategoryId=43753&ref=25 13 October 2009-10-13T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/422009/633542null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Global-Pharma-Market-Growth-to-Grow-4-to-6-Percent/ArticleStandard/Article/detail/632250?contextCategoryId=43753&ref=25 Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates. 2009-10-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/632250null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/H1N1-Vaccine-Hits-the-Market/ArticleStandard/Article/detail/632251?contextCategoryId=43753&ref=25 Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe? 2009-10-07T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/412009/632251null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/iPharm-Execi-QampA-GSKs-Deirdre-Connelly/ArticleStandard/Article/detail/630329?contextCategoryId=43753&ref=25 Just months on the job and GSK’s new president of North American Pharmaceuticals Deirdre Connelly is already making her presence known. Her latest move—spearheading an initiative that will boost funding to autonomous CME programs and cut commercial medical education programs. Pharm Exec spoke with Connelly to find out more. 2009-09-30T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/402009/630329null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/JampJ-Slims-Down-Elan-Offer-sans-Tysabri/ArticleStandard/Article/detail/626746?contextCategoryId=43753&ref=25 Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move. 2009-09-16T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382009/626746null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/IMI-Announces-Next-Topics-for-Research/ArticleStandard/Article/detail/626551?contextCategoryId=43753&ref=25 15 September 2009 2009-09-15T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382009/626551null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Lilly-Shuffles-Staff-Cuts-Thousands-of-Jobs/ArticleStandard/Article/detail/626469?contextCategoryId=43753&ref=25 Eli Lilly announced this morning that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that's expected to net the firm reduce $1 billion in costs by 2011. 2009-09-14T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/382009/626469null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/AstraZeneca-wins-over-UK-doctors/ArticleStandard/Article/detail/625465?contextCategoryId=43753&ref=25 10 September 2009 2009-09-10T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372009/625465null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Sepracor-Faces-Shareholder-Lawsuit-in-Wake-of-26B-/ArticleStandard/Article/detail/625138?contextCategoryId=43753&ref=25 Some shareholders think they were shafted in the multi-billion dollar deal between Sepracor and Dainippon Sumitomo Pharma. They're so miffed, in fact, that they've filed a lawsuit stating that the amount offered undervalues the company and its shares. 2009-09-09T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372009/625138null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Roche-Shifts-Execs-in-Anticipation-of-Departures/ArticleStandard/Article/detail/625139?contextCategoryId=43753&ref=25 With the pending retirement of three senior-level executives, Roche announced a new corporate executive team to bridge the personnel gap while the company looks for new leaders. 2009-09-09T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/372009/625139null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Algeta-amp-Bayer-in-cancer-drug-deal/ArticleStandard/Article/detail/623829?contextCategoryId=43753&ref=25 3rd September 2009 2009-09-03T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362009/623829null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Global-Cancer-Cases-to-Grow-by-30-Per-Cent/ArticleStandard/Article/detail/623601?contextCategoryId=43753&ref=25 2 September 2009 2009-09-02T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/362009/623601null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Guiding-Your-Drug-Name-to-Approval/ArticleStandard/Article/detail/617169?contextCategoryId=43753&ref=25 06 August 2009 2009-08-24T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322009/617169null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Pfizer-to-develop-clinical-trial-website/ArticleStandard/Article/detail/620739?contextCategoryId=43753&ref=25 21 August 2009 2009-08-21T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/342009/620739null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Obama-Advisor-to-Open-Swedish-Life-Sciences-Summit/ArticleStandard/Article/detail/619614?contextCategoryId=43753&ref=25 18 August 2009 2009-08-18T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/342009/619614null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Pfizer-settles-Nigerian-Trovan-case/ArticleStandard/Article/detail/615966?contextCategoryId=43753&ref=25 3 August 2009 2009-08-03T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/322009/615966null HTML http://pharmexec.findpharma.com/pharmexec/Europe/A-busy-time-for-Sanofi/ArticleStandard/Article/detail/615488?contextCategoryId=43753&ref=25 31 July 2009 2009-07-31T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/312009/615488null HTML http://pharmexec.findpharma.com/pharmexec/Deals/GSK-Signs-120M-Deal-to-Market-DMab-Overseas/ArticleStandard/Article/detail/615227?contextCategoryId=43753&ref=25 Amgen's and GSK will partner to market Amgen's blockbuster osteoporosis treatment DMab in Europe, China, and other overseas countries once it is approved. 2009-07-30T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/312009/615227null REMOTE http://pharmexec.findpharma.com/pharmexec/Marketing/Pfizer-Joins-Twitter-Fray/ArticleStandard/Article/detail/615237?contextCategoryId=43753&ref=25 The drug giant, last week, started tweeting about corporate initiatives, job openings, and news. Is Pfizer just jumping on the bandwagon, or is Twitter part of the company's social media strategy? Pharm Exec talks to Pfizer to find out more. 2009-07-29T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/312009/615237null REMOTE http://pharmexec.findpharma.com/pharmexec/News+Analysis/NHLBI-Cans-Sildenafil-Study-After-Reports-of-Sever/ArticleStandard/Article/detail/615239?contextCategoryId=43753&ref=25 Trial participants being treated for pulmonary hypertension suffered sickle cell pain in clinical trial. The cause: the active ingredient in Viagra. 2009-07-29T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/312009/615239null REMOTE http://pharmexec.findpharma.com/pharmexec/News+Analysis/Statins-Get-Boost-from-New-Study/ArticleStandard/Article/detail/613031?contextCategoryId=43753&ref=25 Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal. 2009-07-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/302009/613031null REMOTE http://pharmexec.findpharma.com/pharmexec/Regulatory/New-NIH-Leader-Backs-Personalized-Medicine/ArticleStandard/Article/detail/613034?contextCategoryId=43753&ref=25 Collins seeks to parlay genomic discoveries into new biomedical therapies. Comparative effectiveness research, he says, should identify subpopulation responses to treatment and support personalized medicine. 2009-07-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/302009/613034null REMOTE http://pharmexec.findpharma.com/pharmexec/Europe+News/European-Approval-for-Pfizer-Wyeth-Deal/ArticleStandard/Article/detail/612293?contextCategoryId=43753&ref=25 20 July 2009 2009-07-20T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/302009/612293null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/FDA-Boosts-Warnings-on-Propoxyphene-Pain-Meds/ArticleStandard/Article/detail/609623?contextCategoryId=43753&ref=25 Pain medications containing propoxyphene could lead to overdose and death, according to new labeling mandated by FDA. However, public requests to take these drugs (including Darvon and Darvocet) off the market have been denied. 2009-07-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/609623null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Servier-Singled-Out-for-New-EU-Antitrust-Investiga/ArticleStandard/Article/detail/609542?contextCategoryId=43753&ref=25 08 July 2009 2009-07-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/609542null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Sanofi-Gets-Green-Light-on-Blockbuster-Heart-Treat/ArticleStandard/Article/detail/609625?contextCategoryId=43753&ref=25 Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it. 2009-07-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/282009/609625null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Abbott-to-Pay-167B-in-Patent-Suit/ArticleStandard/Article/detail/608192?contextCategoryId=43753&ref=25 J&J emerged victorious in a patent suit claiming that the technology behind Abbott's blockbuster arthritis treatment Humira is too similar in design to J&J's Remicade. The cost to Abbott: $1.67 Billion. 2009-07-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/272009/608192null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Sudden-Deaths-and-ADHD-Meds-Not-Necessarily-Relate/ArticleStandard/Article/detail/604388?contextCategoryId=43753&ref=25 Feds claim results of study comparing car crash deaths and children on ADHD drugs were not paramount to pulling kids off of ADHD treatments. 2009-06-17T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/252009/604388null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Oscient-Pharmaceuticals-Lays-Off-180-Reps/ArticleStandard/Article/detail/604392?contextCategoryId=43753&ref=25 Oscient trims 180 sales, marketing, and corporate jobs in the wake of patent expirations, generic competition. 2009-06-17T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/252009/604392null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/UCB-Teams-with-PatientsLikeMe-to-Learn-What-Patien/ArticleStandard/Article/detail/604391?contextCategoryId=43753&ref=25 In an effort to learn as more about epilepsy sufferers, UCB will implement a social network that allows patients to communicate about their disease state and treatments. Think of it as one giant, online clinical trial. 2009-06-17T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/252009/604391null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Merck-signs-discovery-deal-with-Xenon/ArticleStandard/Article/detail/603134?contextCategoryId=43753&ref=25 12 June 2009 2009-06-12T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/603134null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/WHO-Pushes-H1N1-Flu-to-Pandemic-State/ArticleStandard/Article/detail/603039?contextCategoryId=43753&ref=25 The Word Health Organization just bumped the H1N1 influenza to pandemic alert phase 6 (the highest alert level), making it the first worldwide pandemic in 41 years. 2009-06-11T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/603039null REMOTE http://pharmexec.findpharma.com/pharmexec/News+Analysis/Wyeth-Winds-Up-With-New-Pristiq-Campaign/ArticleStandard/Article/detail/602670?contextCategoryId=43753&ref=25 What do you do when you are introducing a new drug in an already crowded category? Wyeth queried depression sufferers to find out what they want to see in a drug ad before launching its new DTC campaign for Pristiq. 2009-06-10T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/602670null HTML http://pharmexec.findpharma.com/pharmexec/Deals/GSK-Teams-with-Shenzhen-Neptunus-for-Chinese-Vacci/ArticleStandard/Article/detail/602668?contextCategoryId=43753&ref=25 GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people. 2009-06-10T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/602668null HTML http://pharmexec.findpharma.com/pharmexec/Europe/A-Cautionary-Tale-for-Executives/ArticleStandard/Article/detail/602420?contextCategoryId=43753&ref=25 9 June 2009 2009-06-09T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/242009/602420null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Pharmaceutical-Execs-Embrace-the-Web/ArticleStandard/Article/detail/601618?contextCategoryId=43753&ref=25 4 June 2009 2009-06-04T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232009/601618null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Pfizer-completes-European-debt-offering/ArticleStandard/Article/detail/601617?contextCategoryId=43753&ref=25 4 June 2009 2009-06-04T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232009/601617null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/FDA-Launches-Transparency-Task-Force/ArticleStandard/Article/detail/601468?contextCategoryId=43753&ref=25 The feds green lit a task force charged with easing the flow of communication between FDA, pharma companies, and the general public. While the team is being billed as a task force for transparency, it?s still unclear what is being revealed. 2009-06-03T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232009/601468null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/ASCO-Roundup-Winners-Losers-and-Also-Rans/ArticleStandard/Article/detail/601559?contextCategoryId=43753&ref=25 Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida. 2009-06-03T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232009/601559null REMOTE http://pharmexec.findpharma.com/pharmexec/Deals/GSK-Signs-Deal-with-Concert-Pharma-to-the-Tune-of-/ArticleStandard/Article/detail/601466?contextCategoryId=43753&ref=25 GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body. 2009-06-03T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232009/601466null HTML http://pharmexec.findpharma.com/pharmexec/Europe/AstraZeneca-and-Merck-form-collaboration/ArticleStandard/Article/detail/600890?contextCategoryId=43753&ref=25 1 June 2009 2009-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232009/600890null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Elan-in-talks-to-sell-stake-to-Bristol/ArticleStandard/Article/detail/600889?contextCategoryId=43753&ref=25 1 June 2009 2009-06-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/232009/600889null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Amgen-and-CDC-to-Spearhead-Anti-infection-Campaign/ArticleStandard/Article/detail/600090?contextCategoryId=43753&ref=25 Cancer patients worry not only about their disease, but also the side effects of the drugs they take to treat it. Now the Centers for Disease Control and Prevention and biologics firm Amgen are partnering on a multi-prong program to get patients to pay attention to another, related, danger: chemo-related infections. 2009-05-27T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/222009/600090null HTML http://pharmexec.findpharma.com/pharmexec/Regulatory/FDA-Releases-Guidance-on-Risk-in-Ads/ArticleStandard/Article/detail/600089?contextCategoryId=43753&ref=25 You know those loud soundtracks and distracting visuals during the safety information in your TV ads? Critics have been complaining about them, and new draft guidance from FDA is calling them a "no-no." 2009-05-27T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/222009/600089null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/No-Such-Thing-as-Free-Drugs/ArticleStandard/Article/detail/599072?contextCategoryId=43753&ref=25 New medicines program may be a beacon of light for the newly jobless, but some wonder what issues might arise from such a ?good gesture.? 2009-05-21T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/212009/599072null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Wrangling-Over-Research-Results/ArticleStandard/Article/detail/599042?contextCategoryId=43753&ref=25 Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion. 2009-05-21T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/212009/599042null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Amylin-Drops-200-Sales-Reps/ArticleStandard/Article/detail/597346?contextCategoryId=43753&ref=25 As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians. 2009-05-07T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/597346null REMOTE http://pharmexec.findpharma.com/pharmexec/News+Analysis/Rx-Scripts-Spike-in-Wake-of-Swine-Flu/ArticleStandard/Article/detail/597347?contextCategoryId=43753&ref=25 New prescriptions for antiviral treatments get huge boost due to H1N1 epidemic. Numbers exceed those seen during this year's influenza season, and the numbers are climbing. 2009-05-07T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/597347null REMOTE http://pharmexec.findpharma.com/pharmexec/Online+Only/Bio-Companies-Low-on-Venture-Capital-Cash/ArticleStandard/Article/detail/596953?contextCategoryId=43753&ref=25 As the economy continues to retract, fewer biotech companies are finding the funding they need to survive, driving more firms to sell or close shop. 2009-05-06T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/192009/596953null HTML http://pharmexec.findpharma.com/pharmexec/Online+Only/Higher-Learning-for-Pharma-Sales-Reps/ArticleStandard/Article/detail/595662?contextCategoryId=43753&ref=25 American Society of Hypertension to launch new education program that grants sales reps hypertension accreditation after rigorous training. 2009-04-29T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/182009/595662null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Ortho-McNeil-Launches-Facebook-Site-for-Adult-ADHD/ArticleStandard/Article/detail/595660?contextCategoryId=43753&ref=25 Ortho-McNeil is reaching out to the adult ADHD segment through the popular social networking site. The plan is to grow followers through education and unbranded information. Pharm Exec takes a look at the new site. 2009-04-29T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/182009/595660null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pharma-Steps-Up-to-Help-With-Swine-Flu/ArticleStandard/Article/detail/595659?contextCategoryId=43753&ref=25 As the US government weighs its options on whether to commission a vaccine for the new H1N1 strain of influenza, pharma companies gear up for a possible epidemic. 2009-04-29T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/182009/595659null HTML http://pharmexec.findpharma.com/pharmexec/Deals/GSK-Grabs-Derma-Firm-for-29-Billion/ArticleStandard/Article/detail/586391?contextCategoryId=43753&ref=25 Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line. 2009-04-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/112009/586391null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/US-Pharma-Market-To-Decline-in-2009/ArticleStandard/Article/detail/594628?contextCategoryId=43753&ref=25 IMS has revised its 2009, forecast and the outlook isn't pretty for the United States, which looks to drop 1 to 2 percent in the coming year. 2009-04-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/172009/594628null HTML http://pharmexec.findpharma.com/pharmexec/Deals/Pfizer-and-Glaxo-Join-Forces-in-HIV-Venture/ArticleStandard/Article/detail/594629?contextCategoryId=43753&ref=25 The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market. 2009-04-22T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/172009/594629null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/JampJ-Eliminates-900-Sales-Positions/ArticleStandard/Article/detail/593480?contextCategoryId=43753&ref=25 In an effort to realign its sales division to reflect the current pharma environment—smaller, faster, better—Johnson & Johnson is trimming its sales force. 2009-04-15T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/162009/593480null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Boehringer-Ingelheim-Launches-New-Site-for-TIA-Suf/ArticleStandard/Article/detail/593490?contextCategoryId=43753&ref=25 Rather than ignore its aging mini-stroke medication Aggrenox, BI has shifted marketing to education by launching an unbranded site dedicated to informing sufferers about transient ischemic attacks, better known as TIA. 2009-04-15T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/162009/593490null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Search-Ad-Warnings-Leave-Pharma-in-Online-Void/ArticleStandard/Article/detail/593482?contextCategoryId=43753&ref=25 After last week’s flurry of FDA warning letters directed at companies marketing through search ads, industry is left wondering what can be done be done to target patients online? 2009-04-15T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/162009/593482null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pharma-Companies-Hit-With-Warnings-for-Search-Mark/ArticleStandard/Article/detail/592363?contextCategoryId=43753&ref=25 FDA is cracking down on content in search engine advertisements. The argument is that there is a serious deficiency of risk information in the tiny link ads that appear on search ads. With pharma already wary of marketing online, will FDA’s tactic hurt future Web campaigns? 2009-04-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/152009/592363null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Begins-Wyeth-Integration-with-New-Research-/ArticleStandard/Article/detail/592362?contextCategoryId=43753&ref=25 Just two months after the purchase of Wyeth, Pfizer breaks its research division into two—one for large molecules and vaccines, and another for small molecules—with Wyeth and Pfizer execs at the helms. 2009-04-08T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/152009/592362null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Shire-Joins-with-GSK-to-Promote-ADHD-Drug/ArticleStandard/Article/detail/590836?contextCategoryId=43753&ref=25 Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle. 2009-04-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/142009/590836null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Prescription-Abandonment-Numbers-on-the-Rise/ArticleStandard/Article/detail/590840?contextCategoryId=43753&ref=25 Compliance woes and stingy insurance providers are walloping the pharmaceutical industry. But now another nuisance is rearing its ugly head, as a high number of patients are ignoring their doctor's orders and dropping their prescriptions on purpose. 2009-04-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/142009/590840null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/FDA-Demands-Pharma-Firms-Pull-Unapproved-Drugs/ArticleStandard/Article/detail/590830?contextCategoryId=43753&ref=25 The Feds are on the warpath, cracking down on pharmaceutical companies that manufacture and market unapproved prescription narcotics. 2009-04-01T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/142009/590830null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Lillys-ZyprexaProzac-Combo-Approved-for-Depression/ArticleStandard/Article/detail/589335?contextCategoryId=43753&ref=25 After repeated requests for additional study information, the wait has paid off: Lilly was approved to sell its bipolar drug Symbyax for treatment-resistant depression. 2009-03-25T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/132009/589335null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Drug-Sales-See-Minimal-Climb-in-2008/ArticleStandard/Article/detail/589333?contextCategoryId=43753&ref=25 Farewell to double-digit growth. Between patent expirations and a sagging economy, sales of prescription drugs grew only 1.3 percent last year. 2009-03-25T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/132009/589333null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Massachusetts-Passes-New-Sales-and-Marketing-Rules/ArticleStandard/Article/detail/587894?contextCategoryId=43753&ref=25 The latest state-level attempt to regulate pharma marketing is also the most stringent, requiring both drug and device manufacturers to track and disclose marketing spend. And the state's very important biotech industry is crying foul. 2009-03-18T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/122009/587894null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Pharma-Media-Spend-Falls-184-Percent/ArticleStandard/Article/detail/587891?contextCategoryId=43753&ref=25 With the economy in turmoil, pharmaceutical manufacturers are reassessing where and how they spend their advertising dollars. 2009-03-18T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/122009/587891null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Fixing-Pfizers-Rep/ArticleStandard/Article/detail/587895?contextCategoryId=43753&ref=25 Pharm Exec sits down with Kathryn Metcalfe, Pfizer's new vice president of corporate reputation and policy communications to discuss the new position, the perception of pharma among laypeople, and what needs to be done to boost public opinion of the drug industry. 2009-03-18T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/122009/587895null HTML http://pharmexec.findpharma.com/pharmexec/Deals/Gilead-Buys-CV-Therapeutics-Update-1/ArticleStandard/Article/detail/587457?contextCategoryId=43753&ref=25 The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion. 2009-03-12T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/122009/587457null REMOTE http://pharmexec.findpharma.com/pharmexec/Deals/Roche-and-Genentech-Seal-the-Deal-for-468-Billion/ArticleStandard/Article/detail/587456?contextCategoryId=43753&ref=25 After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant. 2009-03-05T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/122009/587456null REMOTE http://pharmexec.findpharma.com/pharmexec/News+Analysis/New-Study-Details-Online-Habits-of-Diabetes-Patien/ArticleStandard/Article/detail/584712?contextCategoryId=43753&ref=25 Manhattan Research singled out type 2 diabetes sufferers and their online search patterns; it turns out diabetes patients are less likely to confront doctors about branded drugs they?ve seen in DTC ads, yet more apt to take Lipitor. 2009-03-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102009/584712null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Merck-Takes-Unusual-Merger-Tactic-in-Schering-Deal/ArticleStandard/Article/detail/586378?contextCategoryId=43753&ref=25 The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move? 2009-03-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/112009/586378null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/GSK-Garners-FDA-Warning-Letter-for-Extraterrestria/ArticleStandard/Article/detail/584711?contextCategoryId=43753&ref=25 GlaxoSmithKline received a warning letter for use of misleading imagery in its television ad for Avodart. The Feds felt that comparing prostate size to planets might not be a good idea. 2009-03-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102009/584711null HTML http://pharmexec.findpharma.com/pharmexec/Regulatory/Wyeth-Loses-Preemption-Battle/ArticleStandard/Article/detail/584710?contextCategoryId=43753&ref=25 The Supreme Court ruled in favor of the plaintiff in a case that has had the pharmaceutical industry on pins and needles. The verdict hammered home the fact that even though FDA approves a drug, pharmaceutical companies are responsible for making labels as clear as possible. 2009-03-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102009/584710null HTML http://pharmexec.findpharma.com/pharmexec/Deals/Genentech-and-Roche-May-Be-Close-to-Deal/ArticleStandard/Article/detail/594630?contextCategoryId=43753&ref=25 All signs point to Genentech acquisition. 2009-03-03T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/172009/594630null HTML http://pharmexec.findpharma.com/pharmexec/Deals/Astellas-to-Nominate-Two-Directors-to-CV-Therapeut/ArticleStandard/Article/detail/586380?contextCategoryId=43753&ref=25 Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own. 2009-03-03T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/112009/586380null HTML http://pharmexec.findpharma.com/pharmexec/Deals/Specialty-Firms-Shoot-Down-Big-Money-Bids/ArticleStandard/Article/detail/583391?contextCategoryId=43753&ref=25 CV Therapeutics and Genetech rejected offers from big-name suitors. Are they playing hard to get or are they just not that into them? 2009-02-25T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092009/583391null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pfizer-Pulls-Two-Late-stage-Drugs-from-Development/ArticleStandard/Article/detail/583389?contextCategoryId=43753&ref=25 A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them. 2009-02-25T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092009/583389null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Lilly-Gets-Green-Light-to-Sell-Prasugrel-in-Europe/ArticleStandard/Article/detail/583390?contextCategoryId=43753&ref=25 Lilly's blood thinner earns approval in Europe and challenges Plavix's status as king of the ACS market. 2009-02-25T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092009/583390null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/EMEACanada-Health-Suspend-Raptiva-Sales/ArticleStandard/Article/detail/583392?contextCategoryId=43753&ref=25 After more reports surface that link Raptiva to a deadly brain infection, world drug regulation agencies decide the risks outweigh benefits. 2009-02-25T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092009/583392null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Sanofi-Aventis-and-AZ-Launch-YouTube-Sites/ArticleStandard/Article/detail/582363?contextCategoryId=43753&ref=25 Two pharma companies dabble in online video in two different but effective ways. Sanofi-aventis attempts to reach patients through educational videos, while AZ calls for consumers to upload their own testimonials. 2009-02-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/082009/582363null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Physicians-Continue-to-Limit-Face-Time-with-Reps/ArticleStandard/Article/detail/582358?contextCategoryId=43753&ref=25 SK&A released grim news last week - nearly two-thirds of sales reps are either banned or forced to make an appointment before they can set foot in a doctor?s office. 2009-02-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/082009/582358null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Bayer-to-Run-Corrective-Ad-for-Birth-Control-Pill/ArticleStandard/Article/detail/582362?contextCategoryId=43753&ref=25 FDA reprimanded Bayer for running misleading advertising touting unproven benefits of the contraceptive Yaz. Now the drug company will shell out $20 million for new ads setting the record straight. 2009-02-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/082009/582362null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pharma-Beats-Sunshine-Act-to-the-Punch/ArticleStandard/Article/detail/580863?contextCategoryId=43753&ref=25 Pfizer is the latest addition to Big Pharma's data disclosure club; the drug giant will be disclosing all physician payments that total more that $500 a year. 2009-02-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072009/580863null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GSK-and-KV-Downsize-in-the-Wake-of-Q4-Numbers/ArticleStandard/Article/detail/580858?contextCategoryId=43753&ref=25 GlaxoSmithKline to lay off thousands while embattled KV Pharma drops 40 percent of its work force in latest wave of cuts. 2009-02-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072009/580858null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Publicis-Aligns-in-Messaging-Divisions/ArticleStandard/Article/detail/579480?contextCategoryId=43753&ref=25 Pharma companies are trimming their bloated sales forces by the hundreds. Eyeballing a golden opportunity, Publicis has aligned its independent communications and sales shops under one umbrella, giving pharma a one-stop-shop for filling in sales gaps. Pharm Exec talks to Publicis? Betsy Lane to learn more. 2009-02-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062009/579480null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Chantix-Bounced-From-McCann-to-McGarry-Bowen/ArticleStandard/Article/detail/579478?contextCategoryId=43753&ref=25 Pfizer switched agencies for its popular smoking cessation drug Chantix. While the company is tight lipped about the campaign's new direction, it looks like this may be the end of the tortoise and hare. Does this signal an end to the use of critters in pharma ads? 2009-02-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062009/579478null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/King-Pharma-Purges-22-Percent-of-its-Workforce/ArticleStandard/Article/detail/579468?contextCategoryId=43753&ref=25 Facing patent expiry for one of its top drugs and an overabundance of sales staff due to recent acquisitions, King announced that it would eliminate 760 jobs. 2009-02-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062009/579468null HTML